ANAB Stock — Anaptysbio, Inc: Metrics

Market overview

2 metrics

Share price

$55.84

Market cap

$1.62B

Price action

19 metrics

Price change (1W)

-3.7%

Price change (30D)

+1.3%

Price change (3M)

+9.0%

Price change (6M)

—

Price change (YTD)

—

Price change (1Y)

—

Trailing year

Price change (5Y)

—

52-week high

—

52-week low

—

Change from 52-week high

—

Change from 52-week low

—

Annualized volatility

67.2%

Beta

—

RSI (14D)

46.3

Price vs SMA 50

-4.1%

Price vs SMA 200

—

Avg volume (3M)

588,088

Relative volume

0.7

Average dollar volume

$34.04M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

29.10M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

7.0×

reciprocal yield 14.3%

P / book

127.5

reciprocal yield 0.8%

FCF yield

0.3%

TTM · current market cap

Buyback yield

4.0%

P / FCF

368.6

reciprocal yield 0.3%

P / operating cash flow

362.9

reciprocal yield 0.3%

Earnings yield

-1.6%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

4.0%

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-05-12

Profitability

9 metrics

Gross margin

—

Operating margin

17.6%

Trailing 12 months

Net margin

-11.5%

Gross profit (TTM)

—

Operating profit (TTM)

$40.80M

Net income (TTM)

−$26.79M

Trailing 12 months

Diluted EPS (TTM)

$-0.87

FCF margin

1.9%

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-9.62

Growth

11 metrics

Revenue growth YoY

-8.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$232.39M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

-6.4%

Year over year · fewer shares

Revenue CAGR (3Y)

+183.6%

Revenue CAGR (5Y)

+25.6%

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-210.1%

Return on assets

-8.1%

Debt / equity

—

Current ratio

7.6

EBITDA (TTM)

$41.34M

Free cash flow (TTM)

$4.41M

Quick ratio

7.6

Interest coverage

—

Net debt / EBITDA

-6.0

Return on invested capital

—

Trailing 12 months

Net cash

$248.47M

Latest balance sheet

Cash & equivalents

$248.47M

Total assets

$329.68M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

$4.48M

Capital expenditures (TTM)

$69,000

R&D (TTM)

$128.78M

SG&A (TTM)

—

Stock compensation (TTM)

$41.12M

R&D / revenue

55.4%

Stock compensation / revenue

17.7%

Ownership (13F)

3 metrics

13F filers

215

13F filer change QoQ

+7

Institutional ownership

104.0%

Short interest

3 metrics

Short interest

18.3%

Latest settlement · 14.3 days to cover

Days to cover

14.3d

Short-squeeze score

70 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

ANAB · Anaptysbio, Inc

ANAB metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search